Roivant (ROIV) President Eric Venker Exercises Options, Sells 200K Shares

What Happened
Eric Venker, President of Roivant Sciences Ltd. and CEO of Immunovant, reported same‑day option exercises and an open‑market sale on July 27, 2026. He exercised options to acquire 200,000 shares at $3.85 per share (cash paid ≈ $770,000) and sold 200,000 shares in the open market for weighted average proceeds of $6,990,000. The filing also lists a 200,000‑share derivative conversion at $0.00 marked as disposed (see Key Details).

Key Details

• Transaction date: July 27, 2026; Form 4 filed July 29, 2026 (filed within normal two‑business‑day window).
• Option exercise (code M, Acquired): 200,000 shares at $3.85 per share — total cost ≈ $770,000. (Footnote F2: options fully vested.)
• Open‑market sale (code S, Disposed): 200,000 shares sold at weighted average $34.95 — proceeds ≈ $6,990,000. Sale prices ranged $34.62–$35.56 (Footnote F1).
• Additional derivative entry (code M, Disposed): 200,000 shares at $0.00 listed as disposed; filing does not further explain mechanics.
• Shares owned after transaction: Not specified in the provided filing.
• Remarks/Exhibits: Exhibit 24 — Power of Attorney; reporting person offers to provide a breakdown of shares sold at each price within the reported range if requested.

Context
This appears to be a same‑day exercise-and-sell transaction (often called a cashless-style exercise), where options were exercised and shares were sold into the market immediately. The filing is factual and does not state motivations; purchases (exercises) and subsequent sales are common for executives exercising vested options to cover costs/taxes or to realize gains.